ライフサイエンスコーパス: vaccine coverage

1 population decreased during periods of high vaccine coverage.

2 mmission on vaccine safety, which may affect vaccine coverage.

3 tion might cause autism has led to a fall in vaccine coverage.

4 atically in surveillance areas with moderate vaccine coverage.

5 increase and then decrease as a function of vaccine coverage.

6 ted with a 4.0% increase in 1-dose varicella vaccine coverage.

7 terminants of virulence and affect potential vaccine coverage.

8 strategies, such as increasing primary 9vHPV vaccine coverage.

9 nce in countries with intermediary levels of vaccine coverage.

10 seeing resurgence in countries despite high vaccine coverage.

11 tribution for outbreak size as it relates to vaccine coverage.

12 the whole genome of an RNA virus to improve vaccine coverage.

13 particularly in populations with suboptimal vaccine coverage.

14 increasing vaccine coverage, including polio vaccine coverage.

15 y failure to maintain high levels of measles vaccine coverage.

16 95% credible interval: 0.88, 0.98) had lower vaccine coverage.

17 demand for immunisation services and improve vaccine coverage.

18 the past twenty years despite high levels of vaccine coverage.

19 rust needed to ensure adequate and sustained vaccine coverage.

20 most scenarios because of already improving vaccine coverage.

21 ant to reverse the recent trend of declining vaccine coverage.

22 entation of the HBV birth-dose vaccine, full vaccine coverage, access to affordable diagnostics to id

23 We compared vaccine coverage achieved by 2 different delivery strate

24 elimination, countries should maintain high vaccine coverage, adequate surveillance, and rapid respo

25 l as conserved nucleoprotein, to broaden the vaccine coverage against H5N1 viruses.

26 atform would address an unmet need in global vaccine coverage against HIV and other global pathogens.

27 Due to high vaccine coverage almost immediately after vaccine introd

28 residing in the study villages, and catch-up vaccine coverage among 582 susceptible persons 11-30 yea

29 From 2001 through 2008, national 1-dose MMR vaccine coverage among children 19-35 months of age rang

30 Quebec, Canada, where rates of 1- and 2-dose vaccine coverage among children 3 years of age were 95%-

31 By 2000, vaccine coverage among children aged 19 to 35 months was

32 Results: Mean vaccine coverage among children in the LAIV group was 76

33 an papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adolescents has increased but

34 aricella active surveillance sites with high vaccine coverage among young children, the incidence of

35 Increases in county-wide vaccine coverage among younger adults were associated wi

36 ce decreased rapidly with increasing measles vaccine coverage and became low or negligible when cover

37 vated vaccines, which could lead to improved vaccine coverage and control of the disease.

38 Disease Control and Prevention estimates of vaccine coverage and effectiveness) to estimate influenz

39 For mumps control, high vaccine coverage and high population immunity must be ac

40 Further efforts to maximize vaccine coverage and improve vaccine performance in thes

41 should be given to improvements in influenza-vaccine coverage and improvements in the diagnosis and t

42 algia, and aggregated these data to estimate vaccine coverage and incidence of herpes zoster and post

43 ines, that could be beneficial in increasing vaccine coverage and protection and reducing influenza-r

44 hoice of influenza vaccine type may increase vaccine coverage and reduce disease burden, but it is mo

45 f the epidemic and of the known disparity in vaccine coverage and risk of disease, a dual strategy to

46 ntries to maintain high levels of poliovirus vaccine coverage and sensitive surveillance to protect t

47 We estimated vaccine coverage and serotype-specific vaccine-induced p

48 m to identify correlations between trends in vaccine coverage and socioeconomic factors.

49 dy levels in children aged <5 years, and Hib vaccine coverage and timing in children aged 1 to <2 yea

50 f current diphtheria, tetanus, and pertussis vaccine coverage and timing, a 90% efficacious 3-dose ro

51 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every 4-6 yea

52 stigation in one of these villages to assess vaccine coverage and vaccine efficacy and to describe th

53 Our estimates of vaccine coverage and vaccine-induced immunity were based

54 een extremely successful in maintaining high vaccine coverage and, therefore, in keeping the virus fr

55 ses, molecular epidemiology, seroprevalence, vaccine coverage, and adequacy of surveillance--the pane

56 isting epidemiological data, cost estimates, vaccine coverage, and efficacy data, as well as hypothet

57 es of baseline immunity (January-June 2015), vaccine coverage, and vaccine efficacy.

58 lic, especially at-risk people; improved HBV vaccine coverage; and improved viral hepatitis services

59 where the risk of tuberculosis infection and vaccine coverage are also highest.

60 To examine the association of vaccine coverage at 2 years of age and measles incidence

61 Vaccine coverage averaged 63%; excess mortality when the

62 prevented 61% of cases had this same rate of vaccine coverage been achieved and maintained before the

63 en Oct 1, 2012 and Sept 3, 2013; the average vaccine coverage before delivery based on this cohort wa

64 of varicella in populations with increasing vaccine coverage between 1997 and 2005.

65 The gap in measles vaccine coverage between white and nonwhite children was

66 tapopulation model illustrates how increased vaccine coverage, but still below the local elimination

67 ge groups was dominant when choice increased vaccine coverage by >/=3.25%.

68 multiple visits to homes; and monitoring of vaccine coverage by household during the course of the c

69 proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortalit

70 The authors used vaccine coverage data to estimate person-time exposed an

71 To estimate immunity from vaccine coverage data, 95% vaccine efficacy was used for

72 ansmissibility may increase substantially if vaccine coverage drops by as little as 1%.

73 ree used estimates of disease burden, costs, vaccine coverage, efficacy, and price obtained from publ

74 Vaccine coverage for all Expanded Program on Immunizatio

75 ontaining vaccine, estimating and validating vaccine coverage for both the first and second doses of

76 ase severity and population structure on the vaccine coverage for different relative costs of vaccina

77 sing strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such

78 mothers in confirmed cases with estimates of vaccine coverage for the national population of pregnant

79 of neighbouring countries with high and low vaccine coverage further underscore the efficacy of thes

80 While measles vaccine coverage has increased markedly, significant mea

81 Overall, substantial increases in vaccine coverage have occurred since 1970, but notable g

82 ecific incidence, (ii) reemergence with high vaccine coverage, (iii) the possibility for cyclic dynam

83 Despite excellent vaccine coverage in developed countries, whooping cough

84 Vaccine coverage in the population was measured through

85 it was elevated between 1977 and 1986, when vaccine coverage in the United Kingdom was low and epide

86 A 5% decline in MMR vaccine coverage in the United States would result in an

87 in the United States since the early 1990s, vaccine coverage in this population is reported to be lo

88 ation campaigns was successful in increasing vaccine coverage, including polio vaccine coverage.

89 Overall vaccine coverage increased in all six world regions betw

90 Vaccine coverage increased with increasing age and frequ

91 further stratified according to the level of vaccine coverage into high and low coverage strata.

92 Seven countries have 'coldspots' where vaccine coverage is below the WHO target of 80%.

93 Yearly monitoring of influenza vaccine coverage is important to assess the long-term im

94 ion in pregnant women and newborns, reported vaccine coverage is often <50%.

95 Vaccine coverage is relatively static or improving for t

96 recommend vaccination at 14 years and modest vaccine coverage, is poorly documented.

97 With high vaccine coverage, it was not possible to arrive at robus

98 Mounting evidence shows that the best vaccine coverage level for the population as a whole can

99 R values ranging from 1.2 to 1.6 for a given vaccine coverage level.

100 , including diagnostic test characteristics, vaccine coverage, likelihood of receiving a diagnostic t

101 lso examined data on routine and SIA measles vaccine coverage, measles case-based surveillance, and s

102 respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles campaign

103 st that even in low birth rate settings high vaccine coverage must be maintained to avoid an increase

104 h country in the subregion maintains measles vaccine coverage of >/=95%.

105 n municipalities with routine first-dose MMR vaccine coverage of <90%.

106 A minimum vaccine coverage of approximately 80% at the second birt

107 Pneumococcal vaccine coverage of OPSI patients was low overall (42% v

108 ed vaccine development due to apparently low vaccine coverage of type-specific vaccines.

109 As a result, vaccines' coverage of disease burden differed by endpoin

110 Modelling reduced vaccine coverage or the addition of catch-up campaigns s

111 Despite nearly universal vaccine coverage, pertussis rates in the United States h

112 Neighborhood vaccine coverage ranged from 33.6% to 71.0%.

113 Vaccine coverage ranged from 95% to 100% for dose 1 and

114 Further efforts are needed to enhance the vaccine coverage rate in individuals at increased risk o

115 rubella (MMR) and a national cohort study of vaccine coverage rates and timeliness before and after M

116 disease incidence, health care expenditures, vaccine coverage rates, and vaccine efficacy.

117 nce and Great Britain, countries with higher vaccine coverage rates.

118 ination coverage rates to estimate rotavirus vaccine coverage rates.

119 sk populations, yet pediatric and adolescent vaccine coverage remains low.

120 paring the attack rates between high and low vaccine coverage strata irrespective of individuals' vac

121 ng unvaccinated members between high and low vaccine coverage strata.

122 surveys of school entrants (1990-2000), and vaccine coverage surveys of adolescents (1997).

123 e United States in 1999 from serological and vaccine coverage surveys.

124 MMRV vaccine has facilitated improvements in vaccine coverage that will potentially improve disease c

125 he entire village revealed two major gaps in vaccine coverage: the small minority Sunni community and

126 al strategy resulted in narrowing the gap in vaccine coverage to 2% and elimination of endemic diseas

127 tural history of HBV, prevalence, mortality, vaccine coverage, treatment dynamics, and demographics.

128 Influenza vaccine coverage was 27% among children aged 6-23 months

129 Vaccine coverage was 65% in the vaccination only group a

130 HPV vaccine coverage was 84.7% for dose 1, 81.4% for dose 2,

131 Among them, vaccine coverage was 86.3% (95% confidence interval [CI]

132 Hepatitis B vaccine coverage was 93% among 567 children </=10 years

133 d that measles would not be transmitted when vaccine coverage was at least 79%.

134 Vaccine coverage was estimated from data collected throu

135 Over the next 4 years, vaccine coverage was extended to 217 million Africans li

136 0 to 100 times lower in countries where high vaccine coverage was maintained than in countries where

137 Vaccine coverage was modest in these early years followi

138 In 2010, 3-dose vaccine coverage was only 32% among 13-17 year-olds.

139 Vaccine coverage was overestimated because the campaign

140 n at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262,000 deaths

141 For some minority groups and some vaccines, coverage was statistically significantly lower

142 Israel has >95% polio vaccine coverage with the last 9 birth cohorts immunized

143 s, our results suggest that moderate cholera vaccine coverage would be an important element of diseas

144 anufacturing, distribution, and perhaps even vaccine coverage, would be greatly improved with an oral